Login to Your Account

Sofinnova closes new $329M fund for early stage biotech, medtech

By Amanda Pedersen
Senior Staff Writer

Thursday, December 10, 2015

After leading 10 of its portfolio companies to exit in the past three years for a total enterprise value of almost €3 billion, European venture capital firm Sofinnova Partners is now armed with a new €300 million fund.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription